EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab

Krzysztof Selmaj, Karsten Roth, Josef Höfler, Klaus Vitzithum, Rafał Derlacz, Oliver von Richter, Cyrill Hornuss, Johann Poetzl, Barry Singer, Laura Jacobs

BioDrugs · 2024

DOI: 10.1007/s40259-024-00671-4 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift BioDrugs, 2024. Verfasst von Krzysztof Selmaj und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Center of Neurology, University of Warmia & Mazury, Olsztyn, Lodz, Poland. Hauptthemen laut MEDLINE: Natalizumab, Biosimilar Pharmaceuticals. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Hexal AG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A biosimilar medicine is a successor to a reference ('originator'/'original-brand') biologic medicine brought to market once the patent and exclusive marketing rights for the reference have expired. Biosimilar natalizumab (PB006 [biosim-NTZ]; developed by Polpharma Biologics S.A. and marketed globally as Tyruko®; Sandoz) has been developed as a successor to reference natalizumab (Tysabri® [ref-NTZ]; Biogen) and is the first US Food and Drug Administration (FDA)-approved and European Medicines Agency (EMA)-approved biosimilar in neurology. As per the FDA and EMA indications for ref-NTZ, biosim-NTZ is approved to treat relapsing forms of multiple sclerosis (USA, EU) and Crohn's disease (USA only). Approval of biosim-NTZ was based on the 'totality of evidence', a comprehensive body of data collected during the development process, demonstrating similarity to its reference medicine. The foundational step of demonstrating structural and functional similarity between biosim-NTZ and ref-NTZ confirmed identical primary and indistinguishable higher order structures, as well as matching binding affinity to α4β1/α4β7 integrins. Following the confirmation of matching structure and function, pharmacokinetic/pharmacodynamic similarity of biosim-NTZ to ref-NTZ in healthy subjects was demonstrated, with no clinically meaningful differences identified in safety and immunogenicity. A comparative, double-blind, randomized study (Antelope) was also conducted in patients with relapsing-remitting multiple sclerosis and demonstrated matching efficacy, safety, and immunogenicity with no clinically meaningful differences between biosim-NTZ and ref-NTZ. This review presents the totality of evidence that confirmed the biosimilarity of biosimilar natalizumab to its reference medicine, which supported its approval by the FDA and the EMA. [Graphical plain language summary available].

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NatalizumabBiosimilar PharmaceuticalsHumansUnited StatesDrug ApprovalUnited States Food and Drug AdministrationMultiple SclerosisCrohn DiseaseNeurologyMultiple Sclerosis, Relapsing-Remitting

Substanzen

NatalizumabBiosimilar Pharmaceuticals

Autor:innen und Institutionen

  • Department of Neurology, Center of Neurology, University of Warmia & Mazury, Olsztyn, Lodz, Poland.
  • Polpharma Biologics S.A., Gdansk, Poland.
  • Staburo GmbH, Munich, Germany.
  • Hexal AG (a Sandoz company), Holzkirchen, Germany.
  • The MS Center for Innovations in Care, Missouri Baptist Medical Center, St Louis, MO, USA.
  • Hexal AG (a Sandoz company), Holzkirchen, Germany. laura.jacobs@sandoz.com.

Förderung

  • Hexal AG

Zitieren

APA

Selmaj, K., Roth, K., Höfler, J., Vitzithum, K., Derlacz, R., von Richter, O., Hornuss, C., Poetzl, J., Singer, B., & Jacobs, L. (2024). Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab. BioDrugs. https://doi.org/10.1007/s40259-024-00671-4

Vancouver

Selmaj K, Roth K, Höfler J, Vitzithum K, Derlacz R, von Richter O, et al. Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab. BioDrugs. 2024. doi:10.1007/s40259-024-00671-4

BibTeX
@article{Selmaj2024,
  author = {Selmaj, Krzysztof and Roth, Karsten and Höfler, Josef and Vitzithum, Klaus and Derlacz, Rafał and von Richter, Oliver and Hornuss, Cyrill and Poetzl, Johann and Singer, Barry and Jacobs, Laura},
  title = {Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab},
  journal = {BioDrugs},
  year = {2024},
  doi = {10.1007/s40259-024-00671-4}
}
Kostenlos starten →